Ranking Alexa Global: # 3,765,334
Server:nginx...
The main IP address: 139.59.161.255,Your server Australia,- ISP:SRI TLD:com CountryCode:AU
The description :a drug discovery and development company. focused on improving the characteristics of existing drug classes in the areas of cancer and fibrosis....
This report updates in 12-Jul-2018
Created Date: | 2009-08-07 |
Changed Date: | 2017-03-06 |
Geo IP provides you such as latitude, longitude and ISP (Internet Service Provider) etc. informations. Our GeoIP service found where is host redxpharma.com. Currently, hosted in Australia and its service provider is SRI .
Latitude: | -33.867851257324 |
Longitude: | 151.20732116699 |
Country: | Australia (AU) |
City: | - |
Region: | - |
ISP: | SRI |
HTTP Header information is a part of HTTP protocol that a user's browser sends to called nginx containing the details of what the browser wants and will accept back from the web server.
X-XSS-Protection: | 1; mode=block |
X-Content-Type-Options: | nosniff |
Content-Encoding: | gzip |
Transfer-Encoding: | chunked |
Strict-Transport-Security: | max-age=31536000; includeSubDomains; |
Vary: | Accept-Encoding |
Fastcgi-Cache: | EXPIRED |
Server: | nginx |
Connection: | keep-alive |
Link: | |
X-UA-Compatible: | IE=Edge |
Date: | Wed, 11 Jul 2018 20:31:47 GMT |
X-Frame-Options: | SAMEORIGIN |
Content-Type: | text/html; charset=UTF-8 |
soa: | dns1.registrar-servers.com. hostmaster.registrar-servers.com. 2018070900 43200 3600 604800 3601 |
txt: | "v=spf1 include:spf.protection.outlook.com -all" |
ns: | dns1.registrar-servers.com. dns2.registrar-servers.com. |
ipv4: | IP:139.59.161.255 ASN:14061 OWNER:DIGITALOCEAN-ASN - DigitalOcean, LLC, US Country:SG |
mx: | MX preference = 5, mail exchanger = redxpharma-com.mail.protection.outlook.com. |
lon: redx 10.25gbp directorate update and grant of options interim results announced about overview board of directors senior management disease focus cancer fibrosis programmes pipeline cancer rxc004 porcupine – cancer pan-raf shp2 fibrosis rock porcupine – fibrosis rock2 investors investor centre share information regulatory news email alerts report and accounts calendar investor resources aim rule 26 news contact contact us careers about overview board of directors senior management disease focus cancer fibrosis programmes pipeline cancer rxc004 porcupine – cancer pan-raf shp2 fibrosis rock porcupine – fibrosis rock2 investors investor centre share information regulatory news email alerts report and accounts calendar investor resources aim rule 26 news contact contact us careers pioneering transformational drug discovery and development in the areas of cancer and fibrosis rxc004 – clinical phase 1 study ongoing pioneering transformational drug discovery and development in the areas of cancer and fibrosis lead fibrosis programme – pan-rock inhibitor for fibrosis related to ibd cancer fibrosis pipeline gbx 10.25gbp lon : redx 11/07/2018 09:12pm drug discovery and development business creating high value cancer and fibrosis therapeutics more about redx pharma recent news 04 jun 2018 directorate update and grant of options 30 may 2018 interim results announced 24 apr 2018 redx appoints senior astrazeneca executive as ceo view all news copyright © 2018 redx pharma plc | privacy policy | cookie policy website design & build by carr kamasa design ') we use cookies to ensure that we give you the best experience on our website. if you continue without changing your settings, we'll assume that you are happy to receive all cookies. cookie policy. i accept
https://www.redxpharma.com/about/overview/
https://www.redxpharma.com/news/news-centre/
https://www.redxpharma.com/investors/investor-resources/
https://www.redxpharma.com/programmes/porcupine-fibrosis/
https://www.redxpharma.com/disease-focus/cancer/
https://www.redxpharma.com/investors/investor-centre/
https://www.redxpharma.com/investors/aim-rule-26/
https://www.redxpharma.com/about/senior-management/
https://www.redxpharma.com/news-archive/directorate-update-and-grant-of-options/
https://www.redxpharma.com/investors/calendar/
https://www.redxpharma.com/investors/email-alerts/
https://www.redxpharma.com/contact/
https://www.redxpharma.com/programmes/shp2/
https://www.redxpharma.com/disease-focus/fibrosis/
https://www.redxpharma.com/cookie-policy/
carrkamasa.co.uk
Whois is a protocol that is access to registering information. You can reach when the website was registered, when it will be expire, what is contact details of the site with the following informations. In a nutshell, it includes these informations;
Domain Name: REDXPHARMA.COM
Registry Domain ID: 1564869126_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.enom.com
Registrar URL: http://www.enom.com
Updated Date: 2017-03-06T09:27:14Z
Creation Date: 2009-08-07T11:03:08Z
Registry Expiry Date: 2019-08-07T11:03:08Z
Registrar: eNom, Inc.
Registrar IANA ID: 48
Registrar Abuse Contact Email:
Registrar Abuse Contact Phone:
Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited
Name Server: NS67.1AND1.CO.UK
Name Server: NS68.1AND1.CO.UK
DNSSEC: unsigned
URL of the ICANN Whois Inaccuracy Complaint Form: https://www.icann.org/wicf/
>>> Last update of whois database: 2017-09-11T19:18:23Z <<<
For more information on Whois status codes, please visit https://icann.org/epp
NOTICE: The expiration date displayed in this record is the date the
registrar's sponsorship of the domain name registration in the registry is
currently set to expire. This date does not necessarily reflect the expiration
date of the domain name registrant's agreement with the sponsoring
registrar. Users may consult the sponsoring registrar's Whois database to
view the registrar's reported date of expiration for this registration.
TERMS OF USE: You are not authorized to access or query our Whois
database through the use of electronic processes that are high-volume and
automated except as reasonably necessary to register domain names or
modify existing registrations; the Data in VeriSign Global Registry
Services' ("VeriSign") Whois database is provided by VeriSign for
information purposes only, and to assist persons in obtaining information
about or related to a domain name registration record. VeriSign does not
guarantee its accuracy. By submitting a Whois query, you agree to abide
by the following terms of use: You agree that you may use this Data only
for lawful purposes and that under no circumstances will you use this Data
to: (1) allow, enable, or otherwise support the transmission of mass
unsolicited, commercial advertising or solicitations via e-mail, telephone,
or facsimile; or (2) enable high volume, automated, electronic processes
that apply to VeriSign (or its computer systems). The compilation,
repackaging, dissemination or other use of this Data is expressly
prohibited without the prior written consent of VeriSign. You agree not to
use electronic processes that are automated and high-volume to access or
query the Whois database except as reasonably necessary to register
domain names or modify existing registrations. VeriSign reserves the right
to restrict your access to the Whois database in its sole discretion to ensure
operational stability. VeriSign may restrict or terminate your access to the
Whois database for failure to abide by these terms of use. VeriSign
reserves the right to modify these terms at any time.
The Registry database contains ONLY .COM, .NET, .EDU domains and
Registrars.
REGISTRAR eNom, Inc.
SERVERS
SERVER com.whois-servers.net
ARGS domain =redxpharma.com
PORT 43
TYPE domain
DOMAIN
NAME redxpharma.com
CHANGED 2017-03-06
CREATED 2009-08-07
STATUS
clientTransferProhibited https://icann.org/epp#clientTransferProhibited
NSERVER
NS67.1AND1.CO.UK 217.160.80.173
NS68.1AND1.CO.UK 217.160.81.173
REGISTERED yes
The following list shows you to spelling mistakes possible of the internet users for the website searched .